- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: 11β-Hydroxysteroid dehydrogenase type 1.
Displaying page 1 of 1.
EudraCT Number: 2022-000748-32 | Sponsor Protocol Number: SPI-62-CL-2002 | Start Date*: 2023-08-29 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006184-19 | Sponsor Protocol Number: SPI-62-CL-2001 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000299-20 | Sponsor Protocol Number: SPI-62-CL-2003 | Start Date*: 2022-06-23 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: A trial of prednisolone in combination with SPI-62 or placebo in subjects with polymyalgia rheumatica (PMR) | |||||||||||||
Medical condition: polymyalgia rheumatica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001351-31 | Sponsor Protocol Number: ED17/93260 | Start Date*: 2017-09-04 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled phase II pilot trial investigating efficacy, safety and feasibility of 11β-hydroxysteroid dehydrogenase type 1 inhibition by AZD4017 to improve skin f... | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003643-31 | Sponsor Protocol Number: rg_13-022 | Start Date*: 2014-01-22 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH). | |||||||||||||
Medical condition: Idiopathic Intracranial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003060-40 | Sponsor Protocol Number: TICSI | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | |||||||||||||
Full Title: Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition | |||||||||||||
Medical condition: Adverse effects of prescribed glucocorticoid therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
